We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App

In Vitro Confirmation of COVID-19 Drug Candidates Done Using AI-based Screening Technology

By HospiMedica International staff writers
Posted on 23 Apr 2020
Print article
SOM Biotech (Barcelona, Spain) has announced the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replication of the virus. Clinical studies with the three candidates can be initiated immediately. SOM Biotech has applied its artificial intelligence-based screening technology (SOMAIPRO) to identify inhibitors of the 3CL proteases of SARS-CoV-2, SARS-CoV and MERS-CoV viruses as potential candidates to treat COVID-19. The discoveries came as a result of the research conducted jointly by SOM Biotech and the Department of Pharmacy and Pharmaceutical Sciences led by Professor Dong-Hae Shin from Ewha Womans University in South Korea.

Within the three identified and validated drug candidates, one – Eravacycline – is an already approved drug. The second compound – Prexasertib – is in clinical development and the third one – Cynarine – is a natural compound used as a dietary supplement. Therefore, all three drugs can be repurposed to treat COVID-19 and the company is working on the fastest way to prove them in patients. A patent application has been filed to provide a method of use protection for the three compounds worldwide.

“We have joined forces with Professor Dong-Hae Shin from Ewha Womans University to combine our scientific and medical expertise to find new therapies for the treatment of COVID-19,” said Raul Insa, CEO, and Founder of SOM Biotech. “Thanks to our capabilities in screening molecules with our AI-based technology, we have validated active anti-coronavirus compounds. Thus, we look forward to the rapid development of these drugs to be able to provide patients with an effective and safe treatment against the COVID-19 as soon as possible”.

“We are very proud about working on promising COVID-19 treatments and contributing to finding effective, safe and fast solutions due to the importance of the current pandemic situation,” said Professor Dong-Hae Shin from Ewha Womans University. “We decided to start working with SOM Biotech as we are committed to tackling this COVID-19 pandemic leveraging on partners with innovative technologies and excellent know-how.”

Related Links:
SOM Biotech

Print article



view channel
Image: The Stat EMS Basic blood testing system (Photo courtesy of Nova Biomedical)

Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries

Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose,... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.